AROVELLA THERAPEUTIC ORDINARY (ALA) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXTurtle to Clinical Advisory Board&Fiorenza Lead Investigator
other announcement
KalkineArovella Leadership Shift Draws Attention on Clinical Focus
Highlights Leadership transition announced at Arovella Therapeutics Clinical development strategy remains in focus Board signals continuity during transition phase Arovella Therapeutics has announced a leadership transition as the company continues advancing its clinical ambitions and broader biotechnology strategy within the Australian healthcare sector. Australian biotechnology company Arovella Therapeutics (ASX:ALA) has entered a new phase following the appointment of an acting chief...
Notice received under section 249D of the Corporations Act
other announcement
ALA files IND with the U.S. FDA for phase 1 clinical trial
other announcement
Appointment of Dr Andrew Nash as Non-Executive Director
other announcement
Change of Director's Interest Notice x2
director_dealing announcement
ALA Exercises Option for Baylor College of Medicine Assets
other announcement
AGM Interim Chair's Address and CEO & MD Presentation
other announcement
Arovella Progresses ALA-101 Program With Appointment of Phas
other announcement